Because USP22 upregulated p21 expression via PTEN‐MDM2‐p53 signaling in pancreatic cancer, we hypothesized that the combination of USP22 overexpression and MDM2 inhibitor treatment would have an enhanced antipancreatic cancer effect. This evidence concerns the gene USP22 and pancreatic neoplasm.